The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
ViroMissile, Inc.
Duke University
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Eli Lilly and Company
IDEAYA Biosciences
Institut du Cancer de Montpellier - Val d'Aurelle
Daiichi Sankyo
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Oscotec Inc.
Kidney Cancer Research Bureau
Second Life Therapeutics
Innate Pharma
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
DualityBio Inc.
University of Colorado, Denver
M.D. Anderson Cancer Center
Maastricht University Medical Center
Maastricht Radiation Oncology
Washington University School of Medicine
3B Pharmaceuticals GmbH
Jonsson Comprehensive Cancer Center
The Netherlands Cancer Institute
Brigham and Women's Hospital
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
NGM Biopharmaceuticals, Inc
Columbia University
Theratechnologies
Elevation Oncology
Seagen Inc.
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
Poseida Therapeutics, Inc.
Rutgers, The State University of New Jersey
Universidade Federal de Pernambuco
ImmunoGenesis
UNICANCER
Carisma Therapeutics Inc
The New York Proton Center
Pack Health
Zumutor Biologics Inc.
NGM Biopharmaceuticals, Inc
Kyoto Prefectural University of Medicine